<DOC>
	<DOCNO>NCT00781781</DOCNO>
	<brief_summary>The purpose study analyze result incidence severity acute chronic GVHD , ( see addendum II ) disease free survival Alemtuzumab use ( MabCampath® ) haematopoietic transplant unrelated donor reduce intensity conditioning .</brief_summary>
	<brief_title>Alemtuzumab Use ( MabCampath® ) Hematopoietic Transplant Unrelated Donor With Reduced Intensity Conditioning</brief_title>
	<detailed_description>Each patient assign one two dosing schedule total dose drug envisage study . The assignation conventional reduce Alemtuzumab ( MabCampath ) dose do depend age risk suffer GVHD , function variable come general experience . High risk GVHD criterion : Gender incompatibility : male patient female donor . HLA incompatibility : non identical high resolution type HLA A , B , C , DRB1 , DQB1 ( identity le 10/10 allele high resolution ) Age patient equal 55 year Conventional dos high risk ( least one criterion GVHD high risk ) : 100 mg de Alemtuzumab IV total dose 5 , 20 mg fraction , day -8 , -7 , -6 , -5 -4 . Reduced dose low risk case ( criterion GVHD high risk ) : 50 mg de Alemtuzumab IV total dose en 5 fraction 10 mg , day -5 , -4 , -3 , -2 -1 .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Inclusion criterion : Patients haematological lymphoid malignancy allogenic transplantation indication : High risk follicular NHL , mantle HHC low grade NHC ( e.g lymphoplasmacytic , extranodal marginal zone ) . 1 . Disease obtain CR Fludarabine antiCD20 include chemotherapy . 2 . Relapse autologous transplant . 3 . Non candidate autologous transplant 2nd CR ( e.g . mobilization failure , persistent marrow infiltrate ) . Poor prognosis chronic lymphoblastic leukaemia ( CLL ) : Del 11q , Del 17p , complex cariotype ; B symptom , progressive low cell count marrow infiltration , lymphocytosis enlarge lymph node , progressive spleen growth . High grade lymphoma transform low grade non Hodgkin 's lymphoma chronic lymphocitic leukaemia High risk T peripheral lymphoma , IPI &gt; = 2 , non susceptible autologous transplant , relapse autologous transplant Primarily refractory high risk Hodgkin 's disease , relapse patient susceptible autologous transplant relapse autologous transplant . High risk acute mieloblastic leukaemia ( AML ) 1st CR , AMC &gt; = 2 CR , include AML MDS secondary AML . High risk acute lymphoblastic leukaemia ( ALL ) poor response induction chemotherapy ( &gt; 10 % blast day +14 RC day +2835 ) , cytogenetic criterion : Ph+ 11q23 . High risk myelodisplastic syndrome ( SMD ) type RAEB1 AREB2 IPSS &gt; Int1 . For inclusion transplant patient ALL AML must CR , patient MDS must &lt; 10 % blast en la BM , patient lymphoid malignancy must show previous chemosensitivity , PR CR . Patients 40 65 year old . Patients outside age range could include accord participate centre criterion . Patients study population lack compatible related donor , possible compatible unrelated donor ( &gt; =9/10 10 allele high resolution typing : HLAA , B , C , DRB1 , DQB1 ) assign patient risk subgroup . Signed informed consent . Not fulfil follow exclusion criterion . Liver ( ≥ x3 UNL ) , kidney ( GF &lt; 40ml/min ) , cardiac ( LVEF &lt; 40 % ) respiratory ( DLCO &amp; FVC &lt; 40 % expect ) function test impairment . HIV injection . Absence sign informed consent . Progressive disease previous transplant fulfil mention response criterion . Other comorbidities contraindicate CT . Pregnant and/or breastfeed woman pregnancy risk inadequate contraception . Life expectancy &lt; 6 month . Mental psychiatric deficiency impede adequate understanding consent therapy Hypersensitivity show anaphylactic reaction DRUGS use trial . Active infectious process .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Myeloid Lymphoid malignance</keyword>
</DOC>